Improving quality of life for blood cancer patients receiving cellular therapy
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study
NA · Massachusetts General Hospital · NCT05646576
This study is testing a new palliative care program called PEACE to see if it can improve the quality of life for blood cancer patients getting cellular therapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital (other) |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05646576 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of a palliative care intervention, known as PEACE, in enhancing the quality of life for patients with hematologic malignancies such as Lymphoma, Leukemia, or Multiple Myeloma who are undergoing adoptive cellular therapy. Initially, a pilot phase will involve 10 participants receiving the intervention, followed by a randomized assignment of 80 participants into two groups: one receiving the palliative care intervention alongside standard oncology care, and the other receiving only standard care. The study will last up to 2 years and is supported by the American Society of Clinical Oncology.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with a hematologic malignancy who are receiving autologous adoptive cellular therapy at Massachusetts General Hospital.
Not a fit: Patients with impaired cognition or uncontrolled mental illness, or those already receiving palliative care, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the quality of life and overall experiences of patients undergoing adoptive cellular therapy for blood cancers.
How similar studies have performed: Other studies have shown promising results with palliative care interventions in oncology, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older. * Ability to complete surveys in English or with assistance of an interpreter. * Diagnosis of a hematologic malignancy. * Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product. Exclusion Criteria: * Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment. * Already receiving palliative care (PC).
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Patrick C Johnson, MD — Massachusetts General Hospital
- Study coordinator: Patrick C Johnson
- Email: PCJOHNSON@MGH.HARVARD.EDU
- Phone: 617-724-4000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma, Adoptive Cellular Therapy, Palliative Care Intervention, Palliative Care